Cendakimab
CC-93538-EE-002
Phase 3 small_molecule active
Quick answer
Cendakimab for Eosinophilic esophagitis is a Phase 3 program (small_molecule) at Celgene Europe Limited with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Celgene Europe Limited
- Indication
- Eosinophilic esophagitis
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active